HomeCompareVGRLX vs MRK

VGRLX vs MRK: Dividend Comparison 2026

VGRLX yields 4.87% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $29.2K in total portfolio value
10 years
VGRLX
VGRLX
● Live price
4.87%
Share price
$26.85
Annual div
$1.31
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.5K
Annual income
$664.83
Full VGRLX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — VGRLX vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVGRLXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VGRLX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VGRLX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VGRLX
Annual income on $10K today (after 15% tax)
$413.82/yr
After 10yr DRIP, annual income (after tax)
$565.11/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $7,763.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VGRLX + MRK for your $10,000?

VGRLX: 50%MRK: 50%
100% MRK50/50100% VGRLX
Portfolio after 10yr
$42.2K
Annual income
$5,231.49/yr
Blended yield
12.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

VGRLX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VGRLX buys
0
MRK buys
0
No recent congressional trades found for VGRLX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVGRLXMRK
Forward yield4.87%2.76%
Annual dividend / share$1.31$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$27.5K$56.8K
Annual income after 10y$664.83$9,798.13
Total dividends collected$5.8K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VGRLX vs MRK ($10,000, DRIP)

YearVGRLX PortfolioVGRLX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,187$486.85$11,206$366.19$19.00MRK
2$12,479$509.00$12,650$502.35$171.00MRK
3$13,883$530.65$14,407$694.19$524.00MRK
4$15,407$551.74$16,585$967.82$1.2KMRK
5$17,057$572.23$19,342$1,363.89$2.3KMRK
6$18,843$592.09$22,913$1,947.19$4.1KMRK
7$20,774$611.30$27,662$2,823.89$6.9KMRK
8$22,858$629.84$34,159$4,173.35$11.3KMRK
9$25,106$647.68$43,337$6,308.80$18.2KMRK
10$27,528$664.83$56,776$9,798.13$29.2KMRK

VGRLX vs MRK: Complete Analysis 2026

VGRLXStock

This fund invests in international real estate stocks including real estate investment trusts—companies that own office buildings, hotels, and other real estate. REITs often perform differently from other stocks and bonds, so this fund may add diversification to a portfolio already made up of stocks and bonds. A key risk is the fund’s narrow scope; since it invests solely within the real estate industry, it may be more volatile than more broadly diversified stock funds. Because it invests in non-U.S. stocks, including those in developed and emerging markets, the fund can be subject to risks unique to international investing, such as currency risk. Investors may wish to consider this fund as a complement to an already diversified stock portfolio.

Full VGRLX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this VGRLX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VGRLX vs SCHDVGRLX vs JEPIVGRLX vs OVGRLX vs KOVGRLX vs MAINVGRLX vs JNJVGRLX vs ABBVVGRLX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.